Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Moderna vaccine progressing toward FDA approval

The coronavirus vaccine made by Moderna has moved closer to FDA authorization. Moderna would be the second company allowed to begin inoculating the U.S. public,...

| By Kelley Gipson

UConn COVID testing strategy garners praise

Over the fall semester, UConn has administered or tracked more than 42,000 COVID-19 individual and surveillance tests among its student body, helping it successfully complete...

| By Kelley Gipson

BioCT welcomes new member Svigals+Partners

Svigals + Partners, LLP is a full-service architecture firm offering architectural, master planning, interior design and FFE services. With nearly 40 years of professional experience,...

| By Kelley Gipson

Boehringer-Ingelheim acquisitions, collaboration

Boehringer Ingelheim plans to acquire NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™...

| By Kelley Gipson

Moderna’s vaccine highly protective, data show

Recently released data confirm that Moderna’s coronavirus vaccine is highly protective, setting the stage for its emergency authorization this week by federal regulators and the...

| By Kelley Gipson

Thetis wins orphan designation for colitis therapy

Thetis Pharmaceuticals has received an FDA orphan drug designation for TP-317 as a small molecule, oral therapy for treatment of pediatric ulcerative colitis. “We are pleased...

| By Kelley Gipson

Connecticut Innovations continues investments

Connecticut Innovations, the state’s venture capital and lending arm, has made $7.8 million worth of equity investments in its first quarter of fiscal year 2021...

| By Kelley Gipson

AlloMek furthers treatment for neurofibromatosis

Federal regulators have deemed a Woodbridge biotechnology company’s tumor-fighting therapy an ‘orphan’ drug, making it eligible for financial incentives. AlloMek Therapeutics earned the FDA designation...

| By Kelley Gipson

InveniAI® and Kyowa Kirin extend collaboration

InveniAI® and Kyowa Kirin have expanded their collaboration agreement to harness the power of InveniAI’s AI-platform, AlphaMeld®, for novel target discovery. Through this expansion, Kyowa Kirin will...